The use of pharmacokinetic and pharmacodynamic data to optimize the dose and schedule of an EphA2 antibody drug conjugate in-vivo
Year: 2007
Type: article
Source: Molecular Cancer Therapeutics
Institution: Seagen (United States)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2255891139
